Effects of ibopamine eye drops on intraocular pressure and aqueous humor flow in healthy volunteers and patients with open-angle glaucoma.
OBJECTIVE
On the basis of intraocular pressure measurements and fluorophotometry we assessed the effects of 2% ibopamine eye drops on aqueous humor production in normal and glaucomatous eyes.


METHODS
Thirty subjects (15 healthy volunteers and 15 open-angle glaucoma patients with ocular hypertension) were included in a placebo-controlled study with random assignment of treatment from masked containers. All subjects underwent ophthalmologic examinations and intraocular pressure (IOP) measurements. Fluorophotometry was done in both eyes at baseline (without treatment) and during treatment. Each subject was treated with 1 drop of 2% ibopamine in one eye and 1 drop of placebo in the fellow eye 30 minutes before fluorophotometric scans and every hour after the first instillation (for a total of 4 times). Safety was evaluated by recording adverse events and ocular symptoms and signs. Aqueous humor flow data were analyzed using the paired t-test, comparing ibopamine and placebo-treated eyes.


RESULTS
No changes in IOP were detected in normal eyes, whereas glaucomatous eyes showed a mean increase of 4 mmHg (95% CI 3.46-4.51) from baseline. The difference in IOP between healthy eyes and those with glaucoma was significant (p < 0.0001). In normal eyes and patients with glaucoma ibopamine led to a significant increase in aqueous humor flow compared with placebo-treated eyes (p < 0.01). The safety profile of ibopamine was very good.


CONCLUSIONS
The results seem to confirm that ibopamine increases aqueous humor production in normal and glaucomatous eyes, raising IOP only in eyes with glaucoma.
Azevedo
H
H
AIBILI, Clinical Trial Centre, Azinhaga St. Comba, Celas, Coimbra, Portugal.
Ciarniello
M G
MG
Rosignoli
M T
MT
Dionisio
P
P
Cunha-Vaz
J
J
D000328:Adult; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism*; D003846:Deoxyepinephrine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D015590:Fluorophotometry; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage* / Q000009:adverse effects; D009883:Ophthalmic Solutions; D016896:Treatment Outcome
D009184:Mydriatics; D009883:Ophthalmic Solutions; C023487:ibopamine; D003846:Deoxyepinephrine